Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma

被引:0
|
作者
Tam, Andrew [1 ]
Ladbury, Colton [1 ]
Kassardjian, Ari [1 ]
Modi, Badri [2 ]
McGee, Heather [1 ]
Melstrom, Laleh [3 ]
Margolin, Kim [4 ]
Xing, Yan [5 ]
Amini, Arya [1 ]
机构
[1] City Hope Comprehens Canc Ctr, Dept Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] City Hope Comprehens Canc Ctr, Dept Dermatol, 1500 E Duarte Rd, Duarte, CA 91010 USA
[3] City Hope Comprehens Canc Ctr, Dept Surg, 1500 E Duarte Rd, Duarte, CA 91010 USA
[4] St Johns Canc Inst, 2121 Santa Monica Blvd, Santa Monica, CA 90404 USA
[5] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, 1500 E Duarte Rd, Duarte, CA 91010 USA
关键词
melanoma; immunotherapy; TVEC; radiotherapy; IMMUNOTHERAPY; RESPONSES;
D O I
10.3390/cancers16111951
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Talimogene laherparepvec (TVEC), a modified virus, is a local injected therapy that has been demonstrated to be an effective treatment in patients with advanced melanoma. Recent reports have suggested that radiation treatment (RT) may activate the immune system when combined with TVEC to further improve both local and systemic responses. However, studies on the combined effect of TVEC and RT remain limited. Here, we reviewed twenty melanoma patients who had received TVEC and RT (fourteen patients to the same region and six patients to different regions of the body) and found a benefit in progression-free survival (PFS) and time to distance metastasis (DM) with a combined regional approach of TVEC and RT. These results suggest that the regional approach of using these two treatment modalities may confer a therapeutic benefit.Abstract Talimogene laherparepvec (TVEC) is a genetically modified oncolytic herpes simplex virus (HSV-1) that is used for the intralesional treatment of advanced or metastatic melanoma. Given that TVEC produces the granulocyte-macrophage colony-stimulating factor (GM-CSF), recent reports have suggested that radiation treatment (RT) given in conjunction with TVEC may provide synergistic immune activation at the site, and possibly systemically. However, studies on combining RT with TVEC remain limited. We conducted a retrospective review of melanoma patients from a single cancer center who received TVEC and RT in the same region of the body and compared them to patients who received TVEC with RT at another site (other than the site of TVEC injection). Between January 2015 and September 2022, we identified twenty patients who were treated with TVEC and RT; fourteen patients received TVEC and RT in the same region, and six had treatments in separate regions. Regions were determined at the time of analysis and were based on anatomic sites (such as arm, leg, torso, etc.). Kaplan-Meier analysis of progression-free survival (PFS), analyses of time to distant metastasis (DM), overall survival (OS), and locoregional control (LRC), and the corresponding log-rank test were performed. With a median follow-up of 10.5 months [mos] (range 1.0-58.7 mos), we found an improvement in PFS with TVEC and RT in the same region compared to different regions, which were 6.4 mos (95% CI, 2.4-NR mos) and 2.8 mos (95% CI, 0.7-4.4 mos), respectively; p = 0.005. There was also a significant improvement in DM when TVEC and RT were used in the same region compared to different regions: 13.8 mos (95% CI, 4.6-NR mos) and 2.8 mos (95% CI, 0.7-4.4 mos), respectively (p = 0.001). However, we found no difference in overall survival (OS) between patients who had TVEC and RT in the same region (19.0 mos, 95% confidence interval [CI], 4.1-not reached [NR] mos) and those who received treatments in different regions (18.5 mos, 95% CI, 1.0-NR mos); p = 0.366. There was no statistically significant improvement in locoregional control (LRC) in patients who had TVEC and RT in the same region was 26.0 mos (95% CI, 6.4-26.0 mos) compared to patients who received TVEC and RT in different regions (4.4 mos) (95% CI, 0.7-NR mos) (p = 0.115). No grade 3 or higher toxicities were documented in either group. Overall, there were improvements in PFS and DM when TVEC and RT were delivered to the same region of the body compared to when they were used in different regions. However, we did not find a significant difference in locoregional recurrence or OS. Future studies are needed to assess the sequence and timing of combining RT and TVEC to potentially enhance the immune response both locally and distantly.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Talimogene laherparepvec monotherapy, an elegant alternative to systemic immunotherapy for the treatment of early metastatic melanoma
    Franke, V.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (01) : 20 - 21
  • [42] Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
    Dummer, Reinhard
    Hoeller, Christoph
    Gruter, Isabella Pezzani
    Michielin, Olivier
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (06) : 683 - 695
  • [43] Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma
    Franke, Viola
    Smeets, Philippe M. G.
    van der Wal, Jacqueline E.
    van Akkooi, Alexander C. J.
    MELANOMA RESEARCH, 2020, 30 (06) : 548 - 551
  • [44] Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
    Reinhard Dummer
    Christoph Hoeller
    Isabella Pezzani Gruter
    Olivier Michielin
    Cancer Immunology, Immunotherapy, 2017, 66 : 683 - 695
  • [45] Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma
    Hoffner, Brianna
    Iodice, Gail M.
    Gasal, Eduard
    ONCOLOGY NURSING FORUM, 2016, 43 (02) : 219 - 226
  • [46] Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
    Chesney, Jason A.
    Ribas, Antoni
    Long, Georgina, V
    Kirkwood, John M.
    Dummer, Reinhard
    Puzanov, Igor
    Hoeller, Christoph
    Gajewski, Thomas F.
    Gutzmer, Ralf
    Rutkowski, Piotr
    Demidov, Lev
    Arenberger, Petr
    Shin, Sang Joon
    Ferrucci, Pier Francesco
    Haydon, Andrew
    Hyngstrom, John
    van Thienen, Johannes, V
    Haferkamp, Sebastian
    Guilera, Josep Malvehy
    Rapoport, Bernardo Leon
    VanderWalde, Ari
    Diede, Scott J.
    Anderson, James R.
    Treichel, Sheryl
    Chan, Edward L.
    Bhatta, Sumita
    Gansert, Jennifer
    Hodi, Frank Stephen
    Gogas, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 528 - +
  • [47] Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate
    Parekh, Vishwas
    Gangadhar, Tara
    Kreider, Kristin L.
    Elenitsas, Rosalie
    Chu, Emily Y.
    JAMA DERMATOLOGY, 2017, 153 (07) : 719 - 721
  • [48] Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma
    Seremet, Teofila
    Planken, Simon
    Schwarze, Julia K.
    Jansen, Yanina
    Vandeweerd, Laura
    van den Begin, Robbe
    Tsechelidis, Ioannis
    Lienard, Danielle
    Del Marmol, Veronique
    Neyns, Bart
    MELANOMA RESEARCH, 2019, 29 (01) : 85 - 88
  • [49] Retrospective Analysis of Talimogene Laherparepvec (T-VEC) in Advanced Melanoma: Efficacy, Safety, and Patient Outcomes
    Rahimi, G.
    Garsa, A.
    Kokot, N.
    Hu, Chong J.
    Swanson, M.
    Butcher, K.
    Thomas, J.
    Lim, A.
    In, G.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2025, 73 (01) : 515 - 516
  • [50] Talimogene Laherparepvec (T-VEC) for Patients with advanced Melanoma - complete Remission in a Patient with Organ Transplantation
    Ressler, J.
    Hoeller, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 58 - 59